Drug Topics

APRIL 1, 2025

In an era of persistent medical misinformation, addressing vaccine hesitancy has become a critical challenge for health care professionals.

Vaccines 247

Vaccines Communication 247

Drug Topics

APRIL 16, 2024

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Vaccines 247

Vaccines FDA 247

Drug Topics

MARCH 27, 2025

Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at Virginia Commonwealth University, discusses the current landscape of immunization recommendations.

Vaccines 247

Vaccines Immunization 247

Drug Topics

FEBRUARY 13, 2025

More detailed information can be found on the CDCs website at www.cdc.gov/vaccines.

Immunization 247

Immunization Vaccines 247

Drug Topics

OCTOBER 26, 2024

The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.

Vaccines 247

Vaccines 247

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

Vaccines 122

Vaccines 122

STAT

JUNE 10, 2024

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses. Continue to STAT+ to read the full story…

Immunization 144

Immunization Vaccines 144

DiversifyRx

MARCH 4, 2025

And when you set the right goals, 2025 could be the year you finally break free from PBM madness, build a loyal patient base, and boost your pharmacy profits. For example, if your goal is to grow your immunization program, don’t just say, “I want to do more vaccines.” Better: Hit 750 vaccines by Q4.

Vaccines 52

Vaccines Immunization Independent Pharmacies FDA 52

Pharmacy Times

MARCH 23, 2025

Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

Vaccines 73

Vaccines Immunization 73

STAT

MARCH 5, 2024

When Americans line up for flu vaccines next fall, they will almost certainly be getting vaccines that no longer contain protection against a family of flu viruses that appears to be extinct.

Vaccines 132

Vaccines FDA 132

PhRMA

MARCH 10, 2025

Measles was declared eliminated in the United States in 2000, thanks to widespread vaccination with the MMR vaccine. Unfortunately, in recent weeks, there has been an alarming increase in measles cases across the country – from Texas and New Mexico to New York and Rhode Island and the first reported death in a decade.

Vaccines 146

Vaccines 146

pharmaphorum

FEBRUARY 27, 2025

An FDA advisory committee due to be held in March to discuss the formulation of influenza vaccines for the 2025/26 flu season has been cancelled.

Vaccines 110

Vaccines FDA 110

European Pharmaceutical Review

DECEMBER 22, 2022

has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. It also has potential to develop vaccines for other respiratory diseases, such as flu and respiratory syncytial virus. Moderna, Inc.

Vaccines 131

Vaccines 131

Pharmacy Times

SEPTEMBER 2, 2024

Robert Walker discusses the updated COVID-19 vaccines targeting the new JN.1 1 lineage of the virus and the challenges of addressing vaccine hesitancy to protect individuals and communities.

Vaccines 90

Vaccines 90

Pharmacy Times

JULY 23, 2024

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

Vaccines 94

Vaccines 94

pharmaphorum

DECEMBER 22, 2022

Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna. The first vaccines are due to be produced at the new facility in 2025.

Vaccines 122

Vaccines 122

Pharmacy Times

APRIL 16, 2024

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

Vaccines 94

Vaccines FDA 94

pharmaphorum

MARCH 14, 2025

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season, without the input of its external advisors

Vaccines 80

Vaccines FDA 80

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. Step forward on vaccines. The post AstraZeneca to supply nine million more vaccines to EU appeared first on.

Vaccines 115

Vaccines 115

pharmaphorum

DECEMBER 1, 2021

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.

Vaccines 105

Vaccines FDA 105

European Pharmaceutical Review

OCTOBER 6, 2023

Positive interim results from Moderna’s Phase I/II trial of mRNA-1083 , an investigational vaccine designed to immunise against both influenza and COVID-19, have been released. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

Pharmacy Times

JANUARY 27, 2025

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Vaccines 82

Vaccines 82

Pharmacy Times

JANUARY 15, 2025

mRNA-1345 (mRESVIA; Moderna) has the potential to significantly transform the RSV disease state in 2025, according to data analysts.

Community Pharmacies 73

Community Pharmacies Vaccines 73

STAT

JUNE 10, 2024

… Moderna announced that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines targeting those viruses , STAT says. A combo shot could improve uptake of both flu and Covid vaccines.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

STAT

OCTOBER 11, 2023

A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine claims that regulators gave its procedures a clean bill of health during a recent inspection. Care Access served as a contract research organization and had enrolled about 3,000 patients in the late-stage trial.

Vaccines 114

Vaccines 114

Fierce Pharma

OCTOBER 24, 2023

On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. | On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year.

Vaccines 93

Vaccines FDA 93

pharmaphorum

FEBRUARY 17, 2025

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

Vaccines 75

Vaccines FDA 75

European Pharmaceutical Review

MARCH 6, 2023

” Post-construction, the facility “will harness mRNA science that aims to develop and deliver innovative vaccines to the UK public that address emerging threats from respiratory viruses.” The Moderna Innovation and Technology Centre is expected to become operational in 2025.

Vaccines 98

Vaccines FDA 98

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Vaccines 98

Vaccines 98

Fierce Pharma

JUNE 29, 2023

While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.

Vaccines 77

Vaccines Immunization 77

DiversifyRx

JANUARY 9, 2025

Top 2024 Blogs on PBM Optimization: “ The Pharmacy Owners Guide to Navigating PBM Headaches in 2025 “ PBMs are still in your future, so get a practical guide so they cause you fewer headaches. “ DSCSA Implementation ” from LSPedia and Dr. Lisa Faast Follow LSPedia for all DSCSA updates and regulation know-how.

Independent Pharmacies 52

Independent Pharmacies Vaccines 52

Fierce Pharma

AUGUST 23, 2023

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix.

Vaccines 72

Vaccines 72

pharmaphorum

MARCH 3, 2025

The "Deep Dive: Research and Development 2025" explores cheminformatics, vaccination history, and birth control. Plus 12 questions with Laura Starkie from UCB. Stay informed about the latest innovations and breakthroughs in these areas.

Vaccines 52

Vaccines 52

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunization 80

Pharmacy Times

MARCH 22, 2025

Pharmacists can empower patient RSV vaccination through strategic communication and personalized care.

Vaccines 50

Vaccines Communication 50

Fierce Pharma

AUGUST 19, 2024

With its rapid development of the Jynneos vaccine, Bavarian | After the WHO declared mpox a global health emergency for the second time in 25 months, Bavarian Nordic said it could ramp up manufacturing to supply 12 million doses of its Jynneos vaccine through 2025 to contain the virus in Africa.

Vaccines 85

Vaccines 85